-
公开(公告)号:US20110033431A1
公开(公告)日:2011-02-10
申请号:US12935769
申请日:2009-03-31
申请人: Shinji Nakahira , Yasushi Torii , Yoshitaka Goto , Miho Shinmura , Satomi Munechika , Sachio Okuda , Shunji Kozaki
发明人: Shinji Nakahira , Yasushi Torii , Yoshitaka Goto , Miho Shinmura , Satomi Munechika , Sachio Okuda , Shunji Kozaki
CPC分类号: A61K38/164 , A61K38/4893 , Y02A50/469
摘要: A pharmaceutical preparation for use in a patient who has a neutralizing antibody to a botulinum toxin from type A1 Clostridium botulinum (type A1 botulinum toxin), said preparation comprising as an active ingredient 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX); a medicament for treating a disease with muscle overactivity for use in a patient who has a neutralizing antibody to a type A1 botulinum toxin, said medicament comprising as an active ingredient said A2 NTX; a method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin, said method comprising administering said A2 NTX to the patient; and a method for use of A2 NTX in a patient who has said neutralizing antibody. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation comprising a type A1 botulinum toxin.
摘要翻译: 一种用于患有来自A1型肉毒毒素(A1型肉毒杆菌毒素)的肉毒毒素中和抗体的患者的药物制剂,所述制剂包含来自A2型肉毒毒素(A2NTX)的150kDa A型神经毒素作为活性成分, ; 用于治疗患有肌肉过度活动的疾病的药物,所述疾病用于患有A1型肉毒杆菌毒素的中和抗体的患者,所述药物包含所述A2NXX的活性成分; 用于治疗对A1型肉毒杆菌毒素具有中和抗体的患者的方法,所述方法包括向患者施用所述A2NXX; 以及在具有所述中和抗体的患者中使用A2NTX的方法。 根据本发明,当患者用包含A1型肉毒杆菌毒素的药物制剂治疗时,可以解决由中和抗体对产生的A1型肉毒杆菌毒素引起的临床反应降低的问题。
-
公开(公告)号:US09623075B2
公开(公告)日:2017-04-18
申请号:US13903731
申请日:2013-05-28
申请人: Shinji Nakahira , Yasushi Torii , Yoshitaka Goto , Miho Shinmura , Satomi Munechika , Sachio Okuda , Shunji Kozaki
发明人: Shinji Nakahira , Yasushi Torii , Yoshitaka Goto , Miho Shinmura , Satomi Munechika , Sachio Okuda , Shunji Kozaki
CPC分类号: A61K38/164 , A61K38/4893 , Y02A50/469
摘要: A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX) to the patient. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation containing a type A1 botulinum toxin.
-
公开(公告)号:US20130252902A1
公开(公告)日:2013-09-26
申请号:US13903731
申请日:2013-05-28
申请人: Shinji NAKAHIRA , Yasushi Torii , Yoshitaka Goto , Miho Shinmura , Satomi Munechika , Sachio Okuda , Shunji Kozaki
发明人: Shinji NAKAHIRA , Yasushi Torii , Yoshitaka Goto , Miho Shinmura , Satomi Munechika , Sachio Okuda , Shunji Kozaki
IPC分类号: A61K38/16
CPC分类号: A61K38/164 , A61K38/4893 , Y02A50/469
摘要: A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX) to the patient. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation containing a type A1 botulinum toxin.
摘要翻译: 一种治疗患有A1型肉毒杆菌毒素中和抗体的患者的方法。 该方法包括从A2型肉毒杆菌(A2NTX)向患者施用150kDa的A型神经毒素。 根据本发明,当患者用含有A1型肉毒杆菌毒素的药物制剂治疗时,可以解决由中和抗体对产生的A1型肉毒杆菌毒素引起的临床反应降低的问题。
-
-